Geburtshilfe Frauenheilkd 2011; 71 - O_16
DOI: 10.1055/s-0031-1286471

The Clinical Registry of Uterine Sarcomas of the University Women's Clinic and the Comprehensive Cancer Center Tübingen

FA Taran 1, C Joachim 1, R Rothmund 1, A Hartkopf 1, P Wagner 1, C Walter 1, A Stäbler 2, R Souchon 3, F Mayer 4, D Wallwiener 1, T Fehm 1
  • 1Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
  • 2Department of Pathology, University of Tuebingen, Tuebingen, Germany
  • 3Department of Radiation Oncology, University of Tuebingen, Tuebingen, Germany
  • 4Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany

Introduction:

Uterine sarcomas comprise a heterogeneous group of diseases with different pathology appearance, clinical course and natural history. They account for only 3% of all uterine malignancies. Due to the rareness of the disease and lack of prospective randomized trials, guidelines of therapeutic management are nonexistent. Therefore our working group aimed to establish a clinical registry of all women that undergo treatment for uterine sarcomas at our institution.

Material and methods:

We identified all patients with uterine sarcoma that underwent treatment at our institution between 1983 and 2010. A total of 101 cases of uterine sarcomas were identified. A retrospective medical record review was performed to ascertain sociodemographic and anthropometric variables, as well as to confirm intraoperative and pathologic findings. Furthermore, follow-up and survival data were ascertained.

Preliminary results:

A total of 61 cases of uterine sarcomas were so far analyzed and included in the registry. 23 (37,7%) cases of endometrial stromal sarcoma, 21 (34,4%) cases of uterine leiomyosarcoma, 16 (26,2%) cases of carcinosarcoma and 1 (0,1%) case of an uterine hemangiosarcoma.

Conclusions:

Completed data including patient characteristics, patterns of management, as well as follow-up and survival data will be presented at the meeting. Based on the relative rarity of these tumors, management of these patients should be centralized and must be performed by a multidisciplinary team including gynecologic oncologist, pathologist, medical oncologist and radiation oncologist.